Literature DB >> 26132675

Single-dose ketamine followed by daily D-Cycloserine in treatment-resistant bipolar depression.

Joshua T Kantrowitz1, Batsheva Halberstam, James Gangwisch.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26132675     DOI： 10.4088/JCP.14l09527

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN： 0160-6689            Impact factor:   4.384


× No keyword cloud information.
  17 in total

1.  Ketamine for depression: evidence, challenges and promise.

Authors:  Carlos A Zarate; Mark J Niciu
Journal:  World Psychiatry       Date:  2015-10       Impact factor: 49.548

Review 2.  Ketamine and Beyond: Investigations into the Potential of Glutamatergic Agents to Treat Depression.

Authors:  Marc S Lener; Bashkim Kadriu; Carlos A Zarate
Journal:  Drugs       Date:  2017-03       Impact factor: 9.546

Review 3.  Neuropsychiatric Effects of Antimicrobial Agents.

Authors:  Nicholas Zareifopoulos; George Panayiotakopoulos
Journal:  Clin Drug Investig       Date:  2017-05       Impact factor: 2.859

4.  Treatment Resistant Depression with Loss of Antidepressant Response: Rapid-Acting Antidepressant Action of Dextromethorphan, A Possible Treatment Bridging Molecule.

Authors:  Edward C Lauterbach
Journal:  Psychopharmacol Bull       Date:  2016-08-15

Review 5.  Efficacy of ketamine for major depressive episodes at 2, 4, and 6-weeks post-treatment: A meta-analysis.

Authors:  Ashley A Conley; Amber E Q Norwood; Thomas C Hatvany; James D Griffith; Kathryn E Barber
Journal:  Psychopharmacology (Berl)       Date:  2021-03-31       Impact factor: 4.530

Review 6.  Glutamatergic Modulators in Depression.

Authors:  Ioline D Henter; Rafael Teixeira de Sousa; Carlos A Zarate
Journal:  Harv Rev Psychiatry       Date:  2018 Nov/Dec       Impact factor: 3.732

Review 7.  Leveraging Neuroplasticity to Enhance Adaptive Learning: The Potential for Synergistic Somatic-Behavioral Treatment Combinations to Improve Clinical Outcomes in Depression.

Authors:  Samuel T Wilkinson; Paul E Holtzheimer; Shan Gao; David S Kirwin; Rebecca B Price
Journal:  Biol Psychiatry       Date:  2018-09-20       Impact factor: 13.382

Review 8.  Symptomatology and predictors of antidepressant efficacy in extended responders to a single ketamine infusion.

Authors:  Steven J Pennybaker; Mark J Niciu; David A Luckenbaugh; Carlos A Zarate
Journal:  J Affect Disord       Date:  2016-10-26       Impact factor: 4.839

Review 9.  Psychopharmacology and Experimental Therapeutics for Bipolar Depression.

Authors:  Manish K Jha; James W Murrough
Journal:  Focus (Am Psychiatr Publ)       Date:  2019-07-16

Review 10.  Novel Glutamatergic Modulators for the Treatment of Mood Disorders: Current Status.

Authors:  Ioline D Henter; Lawrence T Park; Carlos A Zarate
Journal:  CNS Drugs       Date:  2021-04-26       Impact factor: 5.749
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.